International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023

Thomas P. Burris; Ian Mitchelle S. de Vera; Isabelle Cote; Colin A. Flaveny; Udayanga S. Wanninayake; Arindam Chatterjee; John K. Walker; Nickolas Steinauer; Jinsong Zhang; Laurel A. Coons; Kenneth S. Korach; Derek W. Cain; Anthony N. Hollenberg; Paul Webb; Douglas Forrest; Anton M. Jetten; Dean P. Edwards; Sandra L. Grimm; Sean Hartig; Carol A. Lange; Jennifer K. Richer; Carol A. Sartorius; Marc Tetel; Cyrielle Billon; Bahaa Elgendy; Lamees Hegazy; Kristine Griffett; Nahuel Peinetti; Kerry L. Burnstein; Travis S. Hughes; Sadichha Sitaula; Keitch R. Stayrook; Alexander Culver; Meghan H. Murray; Brian N. Finck; John A. Cidlowski

doi:10.1124/pharmrev.121.000436

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023

Thomas P. Burris, Ian Mitchelle S. de Vera, Isabelle Cote, Colin A. Flaveny, Udayanga S. Wanninayake, Arindam Chatterjee, John K. Walker, Nickolas Steinauer, Jinsong Zhang, Laurel A. Coons, Kenneth S. Korach, Derek W. Cain, Anthony N. Hollenberg, Paul Webb, Douglas Forrest, Anton M. Jetten, Dean P. Edwards, Sandra L. Grimm, Sean Hartig, Carol A. LangeJennifer K. Richer, Carol A. Sartorius, Marc Tetel, Cyrielle Billon, Bahaa Elgendy, Lamees Hegazy, Kristine Griffett, Nahuel Peinetti, Kerry L. Burnstein, Travis S. Hughes, Sadichha Sitaula, Keitch R. Stayrook, Alexander Culver, Meghan H. Murray, Brian N. Finck, John A. Cidlowski

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in awide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding ofNRstructure and signaling. Significance Statement——Nuclear receptors (NRs) are ligand-regulated transcription factors that are critical regulators of myriad physiological processes. NRs serve as receptors for an array of drugs, and in this review, we provide an update on recent research into the roles of these drug targets.

Original language	English (US)
Pages (from-to)	1233-1318
Number of pages	86
Journal	Pharmacological Reviews
Volume	75
Issue number	6
DOIs	https://doi.org/10.1124/pharmrev.121.000436
State	Published - Nov 1 2023

Bibliographical note

Publisher Copyright:
© 2023, American Society for Pharmacology and Experimental Therapy (ASPET). All rights reserved.

Access

10.1124/pharmrev.121.000436

OpenUrl availability

Full text

Cite this

Burris, T. P., de Vera, I. M. S., Cote, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., Korach, K. S., Cain, D. W., Hollenberg, A. N., Webb, P., Forrest, D., Jetten, A. M., Edwards, D. P., Grimm, S. L., Hartig, S., ... Cidlowski, J. A. (2023). International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023. Pharmacological Reviews, 75(6), 1233-1318. https://doi.org/10.1124/pharmrev.121.000436

Burris, TP, de Vera, IMS, Cote, I, Flaveny, CA, Wanninayake, US, Chatterjee, A, Walker, JK, Steinauer, N, Zhang, J, Coons, LA, Korach, KS, Cain, DW, Hollenberg, AN, Webb, P, Forrest, D, Jetten, AM, Edwards, DP, Grimm, SL, Hartig, S, Lange, CA, Richer, JK, Sartorius, CA, Tetel, M, Billon, C, Elgendy, B, Hegazy, L, Griffett, K, Peinetti, N, Burnstein, KL, Hughes, TS, Sitaula, S, Stayrook, KR, Culver, A, Murray, MH, Finck, BN & Cidlowski, JA 2023, 'International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023', Pharmacological Reviews, vol. 75, no. 6, pp. 1233-1318. https://doi.org/10.1124/pharmrev.121.000436

@article{fd362d20597b42babbfa8ac9f417eec6,

title = "International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023",

abstract = "The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in awide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding ofNRstructure and signaling. Significance Statement——Nuclear receptors (NRs) are ligand-regulated transcription factors that are critical regulators of myriad physiological processes. NRs serve as receptors for an array of drugs, and in this review, we provide an update on recent research into the roles of these drug targets.",

author = "Burris, {Thomas P.} and {de Vera}, {Ian Mitchelle S.} and Isabelle Cote and Flaveny, {Colin A.} and Wanninayake, {Udayanga S.} and Arindam Chatterjee and Walker, {John K.} and Nickolas Steinauer and Jinsong Zhang and Coons, {Laurel A.} and Korach, {Kenneth S.} and Cain, {Derek W.} and Hollenberg, {Anthony N.} and Paul Webb and Douglas Forrest and Jetten, {Anton M.} and Edwards, {Dean P.} and Grimm, {Sandra L.} and Sean Hartig and Lange, {Carol A.} and Richer, {Jennifer K.} and Sartorius, {Carol A.} and Marc Tetel and Cyrielle Billon and Bahaa Elgendy and Lamees Hegazy and Kristine Griffett and Nahuel Peinetti and Burnstein, {Kerry L.} and Hughes, {Travis S.} and Sadichha Sitaula and Stayrook, {Keitch R.} and Alexander Culver and Murray, {Meghan H.} and Finck, {Brian N.} and Cidlowski, {John A.}",

year = "2023",

month = nov,

day = "1",

doi = "10.1124/pharmrev.121.000436",

language = "English (US)",

volume = "75",

pages = "1233--1318",

journal = "Pharmacological Reviews",

issn = "0031-6997",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "6",

}

TY - JOUR

T1 - International Union of Basic and Clinical Pharmacology CXIII

T2 - Nuclear Receptor Superfamily—Update 2023

AU - Burris, Thomas P.

AU - de Vera, Ian Mitchelle S.

AU - Cote, Isabelle

AU - Flaveny, Colin A.

AU - Wanninayake, Udayanga S.

AU - Chatterjee, Arindam

AU - Walker, John K.

AU - Steinauer, Nickolas

AU - Zhang, Jinsong

AU - Coons, Laurel A.

AU - Korach, Kenneth S.

AU - Cain, Derek W.

AU - Hollenberg, Anthony N.

AU - Webb, Paul

AU - Forrest, Douglas

AU - Jetten, Anton M.

AU - Edwards, Dean P.

AU - Grimm, Sandra L.

AU - Hartig, Sean

AU - Lange, Carol A.

AU - Richer, Jennifer K.

AU - Sartorius, Carol A.

AU - Tetel, Marc

AU - Billon, Cyrielle

AU - Elgendy, Bahaa

AU - Hegazy, Lamees

AU - Griffett, Kristine

AU - Peinetti, Nahuel

AU - Burnstein, Kerry L.

AU - Hughes, Travis S.

AU - Sitaula, Sadichha

AU - Stayrook, Keitch R.

AU - Culver, Alexander

AU - Murray, Meghan H.

AU - Finck, Brian N.

AU - Cidlowski, John A.

PY - 2023/11/1

Y1 - 2023/11/1

N2 - The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in awide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding ofNRstructure and signaling. Significance Statement——Nuclear receptors (NRs) are ligand-regulated transcription factors that are critical regulators of myriad physiological processes. NRs serve as receptors for an array of drugs, and in this review, we provide an update on recent research into the roles of these drug targets.

AB - The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in awide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding ofNRstructure and signaling. Significance Statement——Nuclear receptors (NRs) are ligand-regulated transcription factors that are critical regulators of myriad physiological processes. NRs serve as receptors for an array of drugs, and in this review, we provide an update on recent research into the roles of these drug targets.

UR - http://www.scopus.com/inward/record.url?scp=85178306952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178306952&partnerID=8YFLogxK

U2 - 10.1124/pharmrev.121.000436

DO - 10.1124/pharmrev.121.000436

M3 - Article

C2 - 37586884

AN - SCOPUS:85178306952

SN - 0031-6997

VL - 75

SP - 1233

EP - 1318

JO - Pharmacological Reviews

JF - Pharmacological Reviews

IS - 6

ER -

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this